Canaccord Genuity Maintains Buy on Teladoc Health, Raises Price Target to $11

Benzinga Newsdesk www.benzinga.com Positive 66.3%

Neg 0% Neu 0% Pos 66.3%

Canaccord Genuity analyst Richard Close maintains Teladoc Health (NYSE:TDOC) with a Buy and raises the price target from $10 to $11.